{"id":"thiazide-treatment-group","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"1-5","effect":"Hyponatremia"},{"rate":"rare","effect":"Ototoxicity (high doses)"},{"rate":"1-3","effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thiazides inhibit the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, preventing sodium reabsorption and promoting urinary sodium and water loss. This reduces intravascular volume and peripheral vascular resistance, resulting in lower blood pressure. They also have a direct vasodilatory effect on arterioles that contributes to their antihypertensive action.","oneSentence":"Thiazide diuretics reduce blood pressure by decreasing sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased sodium and water excretion and reduced blood volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:23.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease"}]},"trialDetails":[{"nctId":"NCT07469722","phase":"PHASE2, PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":"Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect","enrollment":128},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT06381934","phase":"NA","title":"Validation of New Diagnostic Indices to Simplify Hyponatremia Therapy Assessment in Patients on Thiazide Diuretics","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-05-06","conditions":"Thiazide Associated Hyponatremia","enrollment":136},{"nctId":"NCT06023576","phase":"PHASE2","title":"A Study of Blood Pressure Control During Cancer Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-08-18","conditions":"Breast Cancer, Cardiotoxicity","enrollment":130},{"nctId":"NCT07199088","phase":"NA","title":"Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2025-10-11","conditions":"Acute Decompensated Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic","enrollment":320},{"nctId":"NCT04676399","phase":"EARLY_PHASE1","title":"Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-08","conditions":"Chronic Pain, Hypertension, Diuretics Drug Reactions","enrollment":36},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT04934228","phase":"PHASE1","title":"Mitigating the Pro-inflammatory Phenotype of Obesity","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-07-01","conditions":"Blood Pressure, Diabetes, Obesity","enrollment":60},{"nctId":"NCT06964217","phase":"","title":"Immediate Fracture Risk After Antihypertensive Drug Initiation","status":"NOT_YET_RECRUITING","sponsor":"Ajou University School of Medicine","startDate":"2025-06-01","conditions":"Hypertension, Fracture","enrollment":10000000},{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":"Essential Arterial Hypertension","enrollment":163},{"nctId":"NCT06608472","phase":"PHASE3","title":"Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Essential Arterial Hypertension","enrollment":292},{"nctId":"NCT06414759","phase":"PHASE4","title":"Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Acute Decompensated Heart Failure, Volume Overload, Edema","enrollment":110},{"nctId":"NCT04647292","phase":"PHASE2","title":"European Blood Pressure Intensive Control After Stroke","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2024-05-02","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":142},{"nctId":"NCT00739674","phase":"PHASE3","title":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":992},{"nctId":"NCT04030234","phase":"NA","title":"Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study","status":"COMPLETED","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2019-09-17","conditions":"Hypertension","enrollment":11255},{"nctId":"NCT00170950","phase":"PHASE3","title":"Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2003-10","conditions":"Hypertension","enrollment":11506},{"nctId":"NCT03999216","phase":"PHASE4","title":"Comparing Diuretic Strategies in Hospitalized Heart Failure","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2023-07","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT03261375","phase":"NA","title":"To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Golden Leaf MedTec Co. Ltd","startDate":"2021-01-19","conditions":"Hypertension","enrollment":205},{"nctId":"NCT05545059","phase":"PHASE3","title":"Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-24","conditions":"Resistant Hypertension","enrollment":138},{"nctId":"NCT03205137","phase":"","title":"Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-06-01","conditions":"Hypertension","enrollment":""},{"nctId":"NCT05352633","phase":"NA","title":"Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-07-18","conditions":"Blood Pressure","enrollment":710},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT02742467","phase":"PHASE4","title":"Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2017-06-07","conditions":"Hypertension","enrollment":702},{"nctId":"NCT03877783","phase":"NA","title":"DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Umeå University","startDate":"2020-10-19","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":10},{"nctId":"NCT03319823","phase":"PHASE4","title":"Treating Nocturnal Hypertension and Nocturia in African American Men","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-10-25","conditions":"High Blood Pressure","enrollment":""},{"nctId":"NCT01206062","phase":"NA","title":"Systolic Blood Pressure Intervention Trial","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-10","conditions":"Hypertension","enrollment":9361},{"nctId":"NCT04465123","phase":"PHASE3","title":"Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-08-13","conditions":"Acute Heart Failure, Acute Kidney Injury","enrollment":100},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04371874","phase":"NA","title":"The Standardized Management of Hypertension in Rural Shaanxi","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2014-01","conditions":"Hypertension","enrollment":1210},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":"The Elderly (≥ 70 Years) With Essential Hypertension","enrollment":241},{"nctId":"NCT03658850","phase":"PHASE2","title":"Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2018-10-01","conditions":"Hypernatremia, Critical Illness","enrollment":184},{"nctId":"NCT03921736","phase":"PHASE4","title":"Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.","status":"COMPLETED","sponsor":"Anna Posadzy-Małaczyńska","startDate":"2000-01-10","conditions":"Hypertension, Hyperuricemia, Menopause","enrollment":180},{"nctId":"NCT02449811","phase":"","title":"RAS Peptide Profiles in Patients With Arterial Hypertension","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Essential Hypertension","enrollment":107},{"nctId":"NCT00923091","phase":"PHASE3","title":"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-06","conditions":"Essential Hypertension","enrollment":2689},{"nctId":"NCT00649389","phase":"PHASE3","title":"Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-05","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT00791258","phase":"PHASE4","title":"A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Hypertension","enrollment":999},{"nctId":"NCT02814552","phase":"NA","title":"OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06-18","conditions":"High Blood Pressure","enrollment":47},{"nctId":"NCT00430638","phase":"PHASE4","title":"A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-12","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00263393","phase":"PHASE4","title":"Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2005-12","conditions":"Myocardial Infarction, Angina Pectoris, Cerebrovascular Accidents","enrollment":3712},{"nctId":"NCT03603444","phase":"","title":"Reliability of Serum Calcium to Phosphorus (Ca/P) Ratio as an Accurate and Inexpensive Tool to Define Disorders of Ca-P Metabolism","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2011-01-01","conditions":"Phosphorus and Calcium Disorders","enrollment":606},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":"Arterial Hypertension","enrollment":144},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT02591628","phase":"NA","title":"Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2015-08","conditions":"Hypertension","enrollment":2027},{"nctId":"NCT01921829","phase":"PHASE4","title":"Protocolized Diuretic Strategy in Cardiorenal Failure","status":"TERMINATED","sponsor":"Kelly V. Liang, MD","startDate":"2013-11","conditions":"Cardiac Failure, Renal Failure, Kidney Failure","enrollment":19},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122},{"nctId":"NCT01480791","phase":"PHASE2","title":"Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2012-01","conditions":"Hypertension, Diabetes","enrollment":""},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT02255253","phase":"NA","title":"Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population","status":"COMPLETED","sponsor":"The George Institute for Global Health, China","startDate":"2014-10","conditions":"Hypertension","enrollment":1410},{"nctId":"NCT02217852","phase":"PHASE4","title":"Treatment of Hypertension in Tibetan Adult Population","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2014-08","conditions":"Hypertension","enrollment":800},{"nctId":"NCT01080742","phase":"","title":"An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-01","conditions":"Hypertension","enrollment":1007},{"nctId":"NCT00926289","phase":"PHASE4","title":"Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Hypertension","enrollment":894},{"nctId":"NCT01219556","phase":"","title":"Xirtam H Combination In the Treatment of Hypertension Evaluation Study.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-11","conditions":"Hypertension","enrollment":8704},{"nctId":"NCT00927537","phase":"","title":"Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Hypertension","enrollment":2052},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT01392534","phase":"","title":"Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":"Primary Hypertension","enrollment":1586},{"nctId":"NCT00797862","phase":"PHASE3","title":"Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":1254},{"nctId":"NCT00942994","phase":"PHASE4","title":"Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Hypertension","enrollment":412},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT00765674","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":1191},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488},{"nctId":"NCT00434967","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Hypertension","enrollment":2207},{"nctId":"NCT00621153","phase":"PHASE4","title":"Candesartan Effect in Second Stage Arterial Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Stage II Hypertension","enrollment":214},{"nctId":"NCT00847834","phase":"PHASE4","title":"Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-12","conditions":"Hypertension","enrollment":968},{"nctId":"NCT00607035","phase":"PHASE4","title":"The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)","status":"COMPLETED","sponsor":"Jichi Medical University","startDate":"2006-05","conditions":"Hypertension","enrollment":220},{"nctId":"NCT00383929","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Hypertension","enrollment":1979}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Thiazide Treatment Group","genericName":"Thiazide Treatment Group","companyName":"Cedars-Sinai Medical Center","companyId":"cedars-sinai-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thiazide diuretics reduce blood pressure by decreasing sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased sodium and water excretion and reduced blood volume. Used for Hypertension, Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}